Quinoline‐1,3‐Oxazole Hybrids: Syntheses, Anticancer Activity and Molecular Docking Studies
Shailesh R. Shah, Kanubhai D. Katariya, D. Prabhakar Reddy
Abstract
Abstract In continuation of the synthesis of potent quinoline based anticancer agents, a series of novel quinoline‐1,3‐oxazole hybrids 15 a ‐ l were synthesized by the condensation reaction of 2‐aryl‐5‐methyl‐1,3‐oxazole‐4‐carbaldehydes 10 a ‐ f and 6‐bromo/6‐chloro‐2‐methyl‐quinolin‐4‐yl‐hydrazines 14 a/b in good yield. Out of twelve, ten of the synthesized compounds were selected by the National Cancer Institute, USA for anticancer activity screening against 60 different human cancer cell lines representing nine types of cancer. Nine compounds were displayed outstanding antiproliferative activity with GI 50 values ranging from 0.26 to 25.6 μ M and LC 50 values ranging from 2.96 μ M to >100 μ M. The mean MG‐MID values of GI 50 , TGI, and LC 50 were compared with the methotrexate and four compounds 15 b , 15 d , 15 e , 15 f emerged with important GI 50 <2.0 μ M. Among all compounds screened, 15 d displayed the highest potency as a cytotoxic molecule. Moreover, new hybrids were also studied for molecular docking into the active binding site of DNA topoisomerase I (htopoI) to understand the binding mode and favorable interactions of active compounds into binding sites of topoisomerase enzyme.